Plus Therapeutics (PSTV) announces that its wholly-owned subsidiary, CNSide Diagnostics will make CNSide cerebrospinal fluid assay platform and testing services commercially available in Texas in August 2025. Initial commercial focus will be on National Cancer Institute Designated Cancer Centers, which treat the highest number of patients at risk for leptomeningeal metastases and previously used CNSide. These institutions and provider networks include the University of Texas – Southwestern, MD Anderson Cancer Center, Mays Cancer Center, Baylor Scott & White Health, and Texas Oncology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics announces $1.6M advance payment from CPRIT
- Plus Therapeutics Advances Pediatric Brain Tumor Treatment with New Clinical Study
- Plus Therapeutics announces initial patients treated in ReSPECT-LM trial
- Plus Therapeutics reaches FDA agreement to initiate ReSPECT-LM trial
- Plus Therapeutics provides business update on CNSide Diagnostics subsidiary